Apixaban Tablet, Film Coated
Product Images NDC 0115-1721

The provided text seems to be a table presenting data on different subgroups of patients who received Apixaban or Warfarin treatment. The table includes information such as the number of events, number of patients, percentage per year, hazard ratio, and confidence intervals for each subgroup. The data is categorized based on factors like age, sex, weight, prior stroke or TIA, diabetes mellitus, CHADS2 score, creatinine clearance, geographic region, and randomization status. The comparison between Apixaban and Warfarin effectiveness in different subgroups is also indicated in the table. Overall, this information can be used to evaluate the efficacy of Apixaban compared to Warfarin in various patient subgroups.*

This text provides information on the interacting drug PK Fold Change and 90% CI for various drugs when combined with P-gp and Strong CYP3A4 Inhibitors such as Ketoconazole or Clarithromycin, as well as other CYP3A4 and P-gp Inhibitors like Diltiazem and Naproxen. It also includes data on combined P-gp and Strong CYP3A4 Inducer Rifampin. The values presented indicate AUC and changes relative to reference levels.*

This text is a table containing information on population description, PK fold change, and recommendations for dose adjustments based on factors such as renal impairment, age, body weight, and hepatic impairment. It outlines specific changes or adjustments for each factor and provides guidance for dosing based on various conditions and demographics.*

This is not a readable text.*